Cloning and expression of hepatitis C virus have allowed the development of immunoassays to detect hepatitis C virus infection. However, currently available recombinant fusion protein C100-3 assays, based on a nonstructural protein of the virus, are limited in sensitivity, particularly for detecting acute infection. In this report seroconversion panels showed that an assay based on synthetic peptides, derived from immunodominant regions of both capsid and nonstructural proteins, accelerated hepatitis C virus antibody detection by 4-10 weeks. In screening, this enzyme immunoassay increased detection from 47% to 64% in plasmapheresis donors with elevated alanine aminotransferase levels (>100 international units per liter), from 15% to 24% in anti-hepatitis B core antigen-positive blood donors, and from 28% to 42% in renal dialysis patients when compared with nonstructural peptide-based assays. The screening assay was repeatedly reactive for 27 of 2902 volunteer blood donor samples (0.93%); four sera reacted only with the capsid antigen. The peptide test distinguished true from false positive results in agreement with recombinant immunoblot assay in 96% of blood donor samples repeatably reactive on a recombinant hepatitis C virus enzyme immunoassay.
First named hepatitis C in 1974 by Prince et al. (1) , transfusion-related hepatitis not attributable to hepatitis A virus or hepatitis B virus accounts for the majority of transfusiontransmitted disease. The existence of an agent causing non-A, non-B hepatitis (NANBH) was further documented by Alter et al. (2) . The cloning and expression of hepatitis C virus (HCV) have allowed the development of antibody screening immunoassays for the detection of HCV infection (3) , using as solid-phase antigen a fusion polypeptide, expressed by recombinant yeast, of human superoxide dismutase and 363 HCV amino acids derived from the nonstructural region of the viral genome (4) . Initial studies using as antigen this fusion protein, designated C100-3, confirmed HCV as the predominant agent of NANBH (4) (5) (6) (7) . However, these and subsequent studies (8) (9) (10) (11) (12) have shown a number of shortcomings with C100-3-based serological tests, resulting from insufficient sensitivity and specificity.
Recently, additional cloning experiments and the resulting sequences of the N-terminal structural portion of the HCV genome have been reported (13) . These sequences, thought to correspond to capsid and envelope genes by analogy with the structure of a related flavivirus, yellow fever virus, complete our knowledge of the HCV genome. Because carefully selected and characterized antigenic peptides have previously shown their utility in human immunodeficiency virus (HIV) and human T-lymphotropic virus I/II diagnosis (14) (15) (16) (17) (18) (19) , we have used synthetic peptides derived from published HCV genomic sequences encoding both structural (13) and nonstructural (20) proteins to address the deficiencies of the recombinant HCV (rHCV) C100-3 protein-based immunoassays.
MATERIALS AND METHODS Samples. NANBH panel 3 and a seroconversion panel were provided by Harvey Alter (National Institutes of Health, Bethesda). A seroconversion panel from a chimpanzee, which had been experimentally inoculated with 70 ml of a proven infectious factor VIII concentrate known to contain HCV, was provided by Daniel Bradley (Centers for Disease Control, Atlanta). HCV seroconversion panels from plasmapheresis donors were obtained from Serologicals (Clarkston, GA). Alanine aminotransferase (ALT)-elevated, antihepatitis B core antigen (aHBc)-and hepatitis B surface antigen (HBsAg)-positive donor samples were from Boston Biomedica (West Bridgewater, MA). ALT-elevated plasmapheresis donor samples were from North American Biologicals (Miami). Random blood donor samples and confirmed anti-HIV-1 (aHIV-1)-positive donor samples were from the New York Blood Center. Japanese dialysis patient samples were from Y. K. Shimizu (Japanese National Institute of Health). Donor samples screened by rHCV enzyme immunoassay (EIA) were from the American Red Cross Blood Services Northeast Region. Clinical samples of other viral infections were from MD Laboratories (Torrance, CA). Autoimmune patient samples were provided by Nicholas Chiorazzi (North Shore University Hospital, Cornell Medical College).
Peptide Synthesis. Peptide synthesis was accomplished by a stepwise solid-phase procedure on thep-methylbenzhydrylamine (MBHA) resin using Applied Biosystems automated peptide synthesizer model 430-A. The protecting scheme for synthesis, employing t-butyloxycarbonyl (t-BOC) group for the a-NH2 terminus and side-chain-protecting groups for trifunctional amino acids, was as described (14) . Synthetic peptides were analyzed for purity by reverse-phase HPLC on a C18 column. Amino acid analysis, peptide sequencing, and fast atom bombardment mass spectroscopy were used to verify the structure and purity of each peptide.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. well-characterized serum panel (n = 8) derived from individuals with, or at risk for, NANBH infection, as described (22) . ETAs were constructed using an immunoreactive capsid synthetic peptide selected from a region covered by amino acids 1-120 (EIA I), according to the published HCV genome sequence (13); two nonstructural synthetic peptides selected from the NS-3/NS4 region covered by amino acids 1200-1800 (20) (EIA TT); or a combination ofall three (EIA TTT). EIA III was designed for screening purposes, and ETAs I and IT were for confirmatory or comparative testing.
EIA III was tested on a coded panel (no. 3) of pedigreed serum samples, proven capable of transmitting, or resulting from transmission of, NANBH. All six NANBH-implicated samples, including an acute-phase sample, reacted; and all pedigreed negative samples were clearly nonreactive. Seroconversion in a transfusion recipient who contracted NANBH (6) was detected by EIA III 12 weeks after transfusion, -6 weeks after the initial rise in ALT levels. This patient retained high levels of antibody to HCV (aHCV) at signal/cutoff ratios >10 for 10 yr.
Sensitivity. Additional seroconversion panels (Table 1) were tested on all three EIAs to evaluate their relative sensitivity in detecting early HCV infection. Testing of sequential samples from two plasma donors showed that reactivity in EIAs I and III, but not in EIA IT, preceded reactivity in a C100-3 assay by 29-71 days ( (Fig. 1) , was evaluated by EIA ITT. The sensitivity of the assay in detecting acute infection was examined in a group of plasma samples likely to represent early HCV infection (Fig. la) . These samples were obtained (23) , is aHBc (24) . In a group of blood donors positive for aHBc, 23.7% (23/97) were reactive with EIA III (Fig. lb) . In Table 2 , these 97 aHBc-positive donors were further divided into three subgroups according to the presence or absence of HBsAg and aHIV-1. Only 14.9o of donors with aHBc as their sole serological abnormality, but 36.8% with both HBsAg and aHBc reactivity, were reactive with EIA TTT. The group with aHIV-1 and aHBc also showed an increased prevalence (29.0%). In each category, fewer donors were reactive on nonstructural EIA TT than on the combined EIA TTT. Only 6.4% of the group with aHBc reactivity alone were reactive with the nonstructural peptides. HBsAg-positive and aHIVpositive donors were 42.0% and 55.6% reactive, respectively, on EIA III (Fig. 1 c and d) .
A panel of samples from Japanese renal dialysis patients, a group known to have a high probability of chronic infection with HCV (25), was tested on EIA III; 42.7% were reactive (Fig. le) , compared with 28% reactive on the rHCV EIA. Clinical details of six representative patients with chronic hepatitis in this group who were reactive on EIA TTT, but not on the rHCV EIA, are given in Table 3 . Four of the six samples owe their reactivity solely to antigen from the capsid region (Table 3) . Thus, capsid antigen improves sensitivity in detecting chronic, as well as acute, HCV infections.
Specificity. In a control group of clinical samples comprising autoimmune diseases, hepatitis A, cytomegalovirus, Epstein-Barr virus, and varicella zoster virus infections, no reactivity was found to EIA III (Fig. lf) . (Table  4 ). The reactive samples in Fig. 2 aHBs, antibody to HBsAg. Ind, indeterminate; 5-1-1, immunodominant region of C100-03, expressed in E. coli. samples (Table 5) . Results on EIA III agreed with RIBA on 60/61 positive samples and 86/91 negative samples, a concordance rate of 96%. The single discrepant RIBA-positive sample was negative on surrogate tests for NANBH as well as on EIAs I and IL Of the five RIBA-negative, EIA III-reactive samples, all were reactive on EIA II, two were also reactive on EIA I, two were positive for aHBc, and one had an elevated ALT result. EIA III was reactive on all three RIBA indeterminate samples that were positive for the 5-1-1 protein band. Of the 21 RIBA indeterminate samples with C100-3 bands, 5 (23.8%) were reactive on EIA III. The 5-1-1 recombinant component of RIBA is expressed in E. coli, whereas the C100-3 component is expressed in yeast, as is the antigenic component of the rHCV screening assay. The RIBA C100-3 reactivity in some samples not confirmed by peptide assays may be due to cross-reactivity with yeast antigens.
Overall, 41 (56.2%) of the 73 samples that were EIA III reactive also had elevated ALT levels, aHBc, or both, whereas only 6 (5.8%) of the 103 negative samples were positive for HBc, and none of these was confirmed by RIBA. DISCUSSION Synthetic peptides, selected from immunodominant regions of viral pathogens on the basis of optimal immunoreactivity, have been used successfully for detecting specific retroviral infections (14) (15) (16) (17) (18) (19) . Such serological validation has led to the development of synthetic peptide immunoassays for antibodies to HIV-1, HIV-2, and human T-lymphotropic virus types I and II (14) (15) (16) (17) (18) (19) . In this report, the reactivity of EIA III on pedigreed NANBH sera shows that HCV serodiagnosis is yet another application in which synthetic peptides can substitute for recombinant proteins or viral lysates as solid-phase antigen. Several advantages inherent in synthetic peptidebased technology, such as the inclusion of essential sequences only and the degree of purification possible, permit the formulation of immunoadsorbents with high signal/cutoff ratios for maximum sensitivity and specificity (19) .
The capsid region of HCV contains immunodominant, highly conserved epitopes that elicit antibody production early in HCV infection. Insufficient sensitivity of C100-3-based assays, especially in early HCV infection, has manifested as long periods of potential infectivity before the appearance of antibody (6, 10) and as underestimation of the prevalence of HCV infection (8) . Comparison in seroconversion panels of the antibody response to capsid-versusnonstructural peptides shows an improvement that can be measured in weeks or months. Improvement is seen not only in individuals likely to have early HCV infection, such as plasmapheresis donors with elevated ALT, but also in renal dialysis patients, a chronically infected group. Our data show that antibodies to capsid peptide persist at high levels in certain individuals with chronic HCV infection; in cases where antibody to nonstructural regions is also present, capsid peptide provides an additional increase in assay signal. Because the capsid protein sequence is highly conserved (13) , capsid peptides are useful for epidemiological studies in geographically diverse areas: EIA III detected aHCV in both Japanese and American clinical populations in this study.
HCV does not appear to contain a single unique region, such as the transmembrane envelope protein of HIV-1 (14) (15) (16) 19) , which confers both universal high sensitivity in early seroconversion and sustained high levels of response throughout the course of viral infection and disease. The antibody response to HCV infection may resemble that of hepatitis B infection more closely than that of HIV. As with aHBc in hepatitis B infection (26) , early immune response in HCV infection results in antibodies to capsid protein. Later, antibodies to other proteins, such as C100-3 in HCV and HBsAg in hepatitis B virus infection, appear. EIA ITT, with peptides from both nonstructural and capsid proteins, provided greater sensitivity in aHCV screening than peptides from either region alone.
In studies at United States and Australian blood banks, 7% of aHBc-positive donors (27) and 6% of donors with raised ALT activity (27, 28) were reactive in a rHCV EIA. The correlation between rHCV antibody reactivity and elevated ALT levels or aHBc reactivity is less than expected, based on the efficacy of these surrogate tests in decreasing transfusion transmission of NANBH (23, 24, 29) . The principal explanation is inadequate aHCV assay sensitivity due to current exclusive use of nonstructural antigens. In this study, 6 .4% of aHBc-positive donors were reactive in EIA IT, but 14.9% were reactive in EIA III. The additional presence of either HBsAg or aHIV-1 in acHBc-positive donor sera increased the correlation with aHCV. This supports the hypothesis of Stevens and coworkers (24) that aHBc is useful as a surrogate marker for HCV infection because it indicates a risk of hepatitis or other viral exposure, not because of cross-reactivity between HBc antigen and HCV capsid antigens.
HBsAg positivity is not considered a surrogate marker for HCV because blood screening for HBsAg since 1971 (26) has precluded follow-up studies of recipients of HBsAg-positive transfusions. Furthermore, the prevalence of HBsAg in donors is -0.03%, much lower than the estimated prevalence of HCV carriers, based on NANBH transmission rates (29) . Our finding that 42% of HBsAg-positive commercial donors were also reactive for acHCV shows that the incidence of the two viral infections is highly correlated. The prevalence of aHCV among donors with elevated ALT levels varies according to additional factors, such as the extent and persistence of elevation (28) . Among blood donors with elevated ALT, only 22.7% were reactive on EIA III, compared with 64% of plasmapheresis donors selected for ALT levels >100 i.u. per liter. ALT elevation may also be from a transient benign condition or from chronic hepatitis of other origin.
Some patients with liver disease (30) , including that due to autoimmune disease or alcohol abuse (10, 31) , exhibit rHCV EIA reactivity. Nonspecific reactivity may result from the abnormally high immunoglobulin concentrations seen in some forms of liver disease (12), rheumatoid factor (11), or antibodies to superoxide dismutase in some individuals (32) . Among blood donors, only 20-70%o of repeatably reactive samples are positive or indeterminate on more specific assays, such as RIBA (26, 29) . In this study, all random blood donor samples screened repeatably reactive by EIA III were confirmed as positive by peptide neutralization assay, and EIA III agreed with RIBA at a 96% concordance rate in distinguishing true from false positive samples screened by a rHCV ETA.
In summary, the addition ofcapsid peptide to nonstructural gene products increases the sensitivity of HCV antibody detection, not only in acute NANBH but in chronic disease as well. Immunodiagnostic tools such as EIA III should provide an improvement in accurate diagnosis for liver disease, in epidemiological surveillance, and in donor screening for this prevalent and pathogenic virus.
Note. After submission of this manuscript, a paper entitled "Enzymelinked immunosorbent assay for antibodies against the capsid protein of hepatitis C virus with a synthetic oligopeptide" by Okamoto et al. (33) was published, describing the use of a synthetic peptide from the HCV capsid region for serodiagnosis of HCV infection.
